Determinants of absence of dyskinesia in Parkinson’s disease patients with treatment beyond 10 years
Objective: This study aims to explore the determinants for absence of dyskinesia in patients with Parkinson’s disease (PD) based on a large cohort of Chinese…STN-DBS causing persistent dyskinetic movements in OFF-State
Objective: Transient choreatic movements are known as side effects of DBS of the dorsolateral STN in Parkinson disease (PD). Persistent “brittle” dyskinesia have been reported…Nonlinearities in outcome-specific hazard of motor and nonmotor long-term complications of Parkinson’s disease
Objective: To estimate the specific hazard of motor and nonmotor milestones of Parkinson's disease (PD) progression in the long term. Background: Parkinson’s disease greatly varies…Patients experiencing peak-dose dyskinesia use re-distribution of involuntary movement amplitude throughout their body to minimize the functional impact of dyskinesia
Objective: To investigate the presence of a strategy in dyskinesia amplitude re-distribution enabling patients to perform motor tasks. Background: In Parkinson’s disease (PD), occurrence of…Absence of wearing-off in Parkinson’s disease patients with treatment beyond 10 years
Objective: This study aims to explore the determinants for absence of wearing-off in patients with Parkinson’s disease (PD) based on a large cohort of Chinese…West Sweden Parkinson Objective Measurement Registry Study (WestPORTS)
Objective: To study a population representative Parkinson’s Disease (PD) patient cohort characterized with objective 6x24h home measurements using the Parkinson Kinetigraph (PKG, Global Kinetics). To…Levodopa-induced dyskinesia in Parkinson’s disease: Sleep matters
Objective: To investigate the relationship between slow wave activity (SWA) of non-rapid eye movement (NREM) sleep, which underlies adjustment of cortical excitability, and levodopa-induced dyskinesias…Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease
Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)
Objective: To assess the frequency of dyskinesias in a population based-cohort of Parkinson’s disease patients. Background: Levodopa-induced dyskinesias are complications that may impact quality of…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 49
- Next Page »